Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Cervical Dysplasia
Interventions: Nicotine Replacement Therapy, Electronic Cigarettes; Other · Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Chronic Atrial Fibrillation
Interventions: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 12
States / cities: San Francisco, California • Hartford, Connecticut • Clearwater, Florida + 9 more

Conditions: Smoking Cessation, Harm Reduction
Interventions: Nicoderm, Nicorette 4Mg Chewing Gum, Nicorette Lozenge Product, BIDI e-cigarette, on!; Drug · Other
Lead sponsor: Rose Research Center, LLC; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions: Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent); Device
Lead sponsor: Paul S Teirstein, MD; Other
Eligibility: 18 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Peripheral Arterial Disease, Peripheral Vascular Diseases
Interventions: SurVeil Drug Coated Balloon, Angioplasty; Device · Procedure
Lead sponsor: SurModics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Raleigh, North Carolina • Columbus, Ohio • Kingsport, Tennessee

Conditions: Prostate Cancer, HDR
Interventions: High-Dose-Rate Brachytherapy; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Coronary Artery Disease
Interventions: HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter; Device
Lead sponsor: Gentuity, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Tampa, Florida • Lexington, Kentucky • Lebanon, New Hampshire

Conditions: Tobacco Use Disorder, Schizophrenia
Interventions: sensorimotor replacement, 42 mg transdermal nicotine replacement, Placebo transdermal nicotine, usual brand smoking; Behavioral · Drug · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Stroke, Aphasia
Interventions: continuous Theta Burst Stimulation, intermittent Theta Burst Stimulation, Transcranial Magnetic Stimulation Sham, Semantic Feature Analysis; Device · Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Atypical Ductal Hyperplasia (ADH) of the Breast
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Back Pain Lower Back Chronic
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 84
States / cities: Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 71 more

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: Nicotine patch, MK-4334, Placebo patch, Placebo capsule; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Actinic Keratosis
Interventions: Biopsy, Calcipotriene, Fluorouracil; Procedure · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Tucson, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more

Conditions: Postoperative Pain After Breast Reconstruction With Abdominal Flap
Interventions: Fentanyl, Inactive patch; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Macular Degeneration
Interventions: Verteporfin Therapy/ Drug: Bevacizumab; Device
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Nicotine Dependence
Interventions: Sustained Care, Usual Care; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pleural Effusion
Interventions: Routine CT, Routine imaging CT with a 3D printed model, Routine imaging MRI with a 3D printed model, Routine MRI, Routine imaging CT with a VR model, Routine imaging MRI with a VR model; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma and Other Malignant Neoplasms of Skin, Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma of the Skin
Interventions: Skin lesion diagnostic device evaluation; Device
Lead sponsor: VeriSkin, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Pleasanton, California • Walnut Creek, California • Tampa, Florida + 3 more

Conditions: Critical Limb Ischemia
Interventions: Drug Eluting Stent - Below the Knee, Standard PTA Control Arm; Combination Product · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 26
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • San Francisco, California + 21 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Roflumilast 0.3% topical foam; Drug
Lead sponsor: Harrison Dermatology; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Missouri City, Texas

Conditions: Osteoarthritis, Knee
Interventions: Lidoderm, Placebo patch; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 24
States / cities: Birmingham, Alabama • Hueytown, Alabama • Tallassee, Alabama + 21 more

Conditions: Amblyopia
Interventions: Atropine, Eye Patch; Drug · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Nonsmall Cell Lung Cancer
Interventions: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Amblyopia
Interventions: Eye patch, Spectacles; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 3 Years to 7 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Fullerton, California • Durham, North Carolina

Search by objective public record fields.

Smoking Cessation in Women With Gynecological Conditions

CONVERGE Post-Approval Study (PAS)

Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

The SCRIPPS DES REAL WORLD Registry

Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon

A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence

Vis-Rx Post-Market Evaluation

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

Recovery From Post-Stroke Aphasia With rTMS Targeting Left or Right Anterior Temporal Lobe

Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

Smoking Cessation Following Psychiatric Hospitalization

Data Visualization of Kidney and Prostate Tumors Using Routine Pre-Operative Imaging, 3D Printed, and 3D Virtual Reality Models

TruScore Standalone Clinical Study

The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children